CCR2 Antibody (48607) [HRP]
Novus Biologicals, part of Bio-Techne | Catalog # FAB150H
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, Flow Cytometry, Immunohistochemistry
Label
HRP
Antibody Source
Monoclonal Mouse IgG2B Clone # 48607
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
NS0 mouse myeloma cell line transfected with human CCR2
Met1-Leu360
Accession # NP_001116868
Met1-Leu360
Accession # NP_001116868
Specificity
Detects human CCR-2 transfectants but not the parental cell line or CCR-5 transfectants.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Applications for CCR2 Antibody (48607) [HRP]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from ascites
Formulation
PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CCR2
Alternate Names
CC-CKR-2, CCR2, CCR2B, CD192, CKR2, CKR2A, CMKBR2, FLJ78302, MCP-1-R
Gene Symbol
CCR2
Additional CCR2 Products
Product Documents for CCR2 Antibody (48607) [HRP]
Product Specific Notices for CCR2 Antibody (48607) [HRP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...